GlassScriptPhysician profile
Troy K Edwards
NPI 1295859288
$3,540.71
in general payments reported to CMS, 2019-2025
41 companies · $542 in 2025
The $542 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $368 · 2021: $913 · 2022: $485 · 2023: $438 · 2024: $279 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $389.54 | 2019-2025 | Lithovue, Spaceoar Vue System - 10ml |
| Pfizer INC. | $239.68 | 2020-2025 | |
| Tolmar Pharmaceuticals, INC. | $177.40 | 2020-2022 | |
| Janssen Biotech, INC. | $140.97 | 2019-2025 | Erleada |
| Bard Access Systems, INC. | $134.62 | 2019 | |
| Endo Pharmaceuticals INC. | $134.15 | 2019-2024 | Aveed, Xiaflex, Edex |
| Astellas Pharma US INC | $131.62 | 2020-2023 | Myrbetriq, Xtandi |
| Neotract INC. | $126.84 | 2020 | |
| Acell, INC. | $124.99 | 2019 | |
| Coloplast Corp | $123.37 | 2021-2025 | |
| Medtronic USA, INC. | $123.04 | 2019 | |
| Myovant Sciences INC. | $120.00 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $103.96 | 2023-2025 | Orgovyx, Gemtesa |
| Abbvie INC. | $102.09 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $98.23 | 2025 | Adstiladrin |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.